We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

176 hedge funds and large institutions have $1.23B invested in Acorda Therapeutics in 2015 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 50 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 50

33% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 21

4% more funds holding

Funds holding: 170 → 176 (+6)

19% less capital invested

Capital invested by funds: $1.51B → $1.23B (-$283M)

75% less call options, than puts

Call options by funds: $2.15M | Put options by funds: $8.69M

Holders
176
Holders Change
+6
Holders Change %
+3.53%
% of All Funds
4.91%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
28
Increased
69
Reduced
50
Closed
21
Calls
$2.15M
Puts
$8.69M
Net Calls
-$6.55M
Net Calls Change
-$6.55M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$35M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$25.9M
3
SCM
Scopia Capital Management
New York
+$18.3M
4
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
+$16.5M
5
Millennium Management
Millennium Management
New York
+$13.7M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$56.1M
2
TCM
Tekla Capital Management
Massachusetts
-$22.7M
3
EAM
Eagle Asset Management
Florida
-$13.7M
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$9.87M
5
Renaissance Technologies
Renaissance Technologies
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
176
Tower Research Capital (TRC)
New York
$1K -$93.1K -24 Closed
FPFS
177
First Personal Financial Services
North Carolina
$1K – – –
ZB
178
Zions Bancorporation
Utah
$1K – – –
Manulife (Manufacturers Life Insurance)
179
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$735 +$27.1K +7 +3%
TCM
180
Tekla Capital Management
Massachusetts
– -$22.7M -5,674 Closed
Renaissance Technologies
181
Renaissance Technologies
New York
– -$9.48M -2,369 Closed
Jennison Associates
182
Jennison Associates
New York
– -$9.01M -2,252 Closed
AQR Capital Management
183
AQR Capital Management
Connecticut
– -$1.78M -444 Closed
State of Tennessee, Department of Treasury
184
State of Tennessee, Department of Treasury
Tennessee
– -$1.11M -278 Closed
GC
185
Globeflex Capital
California
– -$973K -243 Closed
Two Sigma Advisers
186
Two Sigma Advisers
New York
– -$736K -184 Closed
POA
187
Pergamon Offshore Advisors
New York
– -$532K -133 Closed
TAM
188
Tocqueville Asset Management
New York
– -$500K -125 Closed
TD Asset Management
189
TD Asset Management
Ontario, Canada
– -$340K -85 Closed
VAM
190
Visium Asset Management
New York
– -$333K -83 Closed
ECM
191
Endurant Capital Management
California
– -$320K -80 Closed
PA
192
Profund Advisors
Maryland
– -$303K -76 Closed
QIM
193
Quantitative Investment Management
Virginia
– -$296K -74 Closed
EGM
194
Engineers Gate Manager
New York
– -$207K -52 Closed
PCM
195
Prelude Capital Management
New York
– -$67K -17 Closed
Victory Capital Management
196
Victory Capital Management
Texas
– -$42K -11 Closed
US Bancorp
197
US Bancorp
Minnesota
– -$23.3K -6 Closed
MA
198
MUFG Americas
New York
– -$8K -2 Closed
JG
199
Jefferies Group
New York
– -$3K -1 Closed
DADC
200
D.A. Davidson & Co
Montana
– -$1K – –
4 5 6 7
8

ACOR Hedge Fund Activity: Q3 2015 in Review

176 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2015, worth a combined $1.23B — down 19% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ACOR positions and 21 closed out — a net gain of 7 holders — while 69 added to existing stakes and 50 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $35M. The largest seller was UBS AM, cutting an estimated $56.1M.

  • 176 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2015, up from 170 in Q2 2015.
  • Funds reported $1.23B of Acorda Therapeutics stock for Q3 2015, down 19% quarter-over-quarter.
  • 28 funds opened new Acorda Therapeutics positions in Q3 2015 and 21 closed out, a net change of +7 holders.
  • The largest Acorda Therapeutics buyer in Q3 2015 was Point72 Asset Management, an estimated $35M added.
  • The largest Acorda Therapeutics seller in Q3 2015 was UBS AM, an estimated $56.1M sold.

Based on aggregated 13F filings for Q3 2015.